The controlled reaction parameters employed in this PTA-based kit enables reproducible recovery of >95% of the genomes of single cells and limited DNA input samples with industry-leading uniformity and accuracy.
Key features and benefits of ResolveDNA Whole Genome Amplification Kits include:
Ten single cells were isolated from a human B-lymphocyte cell culture (CEPH1463/NA12878/ GM12878 human genome reference standard). WGA was performed on individual cells, using the ResolveDNA Whole Genome Amplification Kit. WGA products were converted to indexed libraries and subjected to high-coverage whole genome sequencing (WGS) on the Illumina® platform. For the other WGA methods, low-pass WGS data (generated from individual BJ1 fibroblasts), were obtained from a previously published study (Chen, C. et al. Science 2017; 356: 189).
To achieve a fair comparison of the various WGA methods, raw data for all samples were aligned and pre-processed for variant calling using the same pipeline. All metrics shown in the table were generated from randomly subsampled BAM files (300 million reads per cell). Note that the metrics for all the methods other than the ResolveDNA kit are overestimates, due to the way in which data analysis was performed in the original study. ResolveDNA metrics were generated using the first version of the ResolveDNA Whole Genome Amplification Kit. The newer ResolveDNA Whole Genome Single-Cell Core Kit achieves similar metrics with a noted increase of SNV sensitivity to 96%